NLRP3 inflammasome-based therapies by natural products: a new development in the context of cancer therapy

Owida HA 1 , Abed AY 2 , Altalbawy FMA 3 , H M 4 , Abbot V 5 , Jakhonkulovna SM 6 Show all authors , Mohammad SI 7 , Vasudevan A 8 , Khalaf RM 9 , Zwamel AH 10

Affiliations 

  • 1 Department of Medical Engineering, Faculty of Engineering, Al-Ahliyya Amman University, Amman, 19328, Jordan
  • 2 Department of Medical Laboratories Techniques, College of Health and Medical Technology, University of Al Maarif, Ramadi, Al Anbar, 31001, Iraq. ahmed.yassin@uoa.edu.iq
  • 3 Department of Chemistry, University College of Duba, University of Tabuk, Tabuk, Saudi Arabia
  • 4 Department of Biotechnology and Genetics, School of Sciences, JAIN (Deemed to be University), Bangalore, Karnataka, India
  • 5 Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjeri, Mohali, 140307, Punjab, India
  • 6 Department of Neurology, vice rektor of Bukhara State Medical Institute, Bukhara, Uzbekistan
  • 7 Electronic Marketing and Social Media, Economic and Administrative Sciences, Zarqa University, Zarqa, Jordan
  • 8 Faculty of Business and Communications, INTI International University, 71800, Negeri Sembilan, Malaysia
  • 9 Mazaya University College, Nasiriyah, Dhiqar, Iraq
  • 10 Department of Medical Analysis, Medical Laboratory Technique College, the Islamic University, Najaf, Iraq
Naunyn Schmiedebergs Arch Pharmacol, 2025 Mar 21.
PMID: 40116873 DOI: 10.1007/s00210-025-04030-0

Abstract

The leucine-rich repeat containing protein (NLR) canonical inflammasome family includes Nod-like receptor protein 3 (NLRP3). Via the mediation of apoptosis proteins and immunological reactions, it controls the pathogenesis of malignancy. Experimental studies showed a relationship among lymphogenesis, cancer metastasis, and NLRP3 expression. Natural products have also been used as lead-based substances in a number of investigations to speed up the creation of novel, specific NLRP3 inhibitors. Via the mediation of apoptotic proteins and immunological responses, it controls the pathogenesis of malignancy. Moreover, it was recently noted that among human cancers, chemotherapy activates NLRP3. Induction of NLRP3 could encourage the generation of IL-1β and IL-22 to facilitate the propagation of malignancy. Additionally, prior research has demonstrated that the usage of NLRP3 in cancer therapy may result in resistance to drugs. The depletion of NLRP3 could affect the survival of cells. Natural products have been used as lead materials in a number of studies to help generate novel, specific NLRP3 antagonists more quickly. In the present review, we examine the mechanism behind the beneficial effects of the natural substances on the inhibition of cancer growth and progression, with special focus on NLRP3 regulation.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications